Long-Term Safety Study of Rituximab in Subjects with GPA and MPA

Study Findings: The study demonstrated that the safety profile of long-term treatment (up to 4 years) with rituximab was consistent with that of rituximab administered for shorter durations. View Publication.

ClinicalTrials.gov ID: NCT01613599

Study Dates: 2012-2017

Disease(s): Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA)